{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:34:40Z","timestamp":1790271280585,"version":"4.1.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82460130"],"award-info":[{"award-number":["82460130"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82260110"],"award-info":[{"award-number":["82260110"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82425010"],"award-info":[{"award-number":["82425010"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170674"],"award-info":[{"award-number":["82170674"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515013044"],"award-info":[{"award-number":["2024A1515013044"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"National Key Research and Development Program of China","award":["2024YFA1107200"],"award-info":[{"award-number":["2024YFA1107200"]}]},{"name":"National Key Research and Development Program of China","award":["2023YFC2505903"],"award-info":[{"award-number":["2023YFC2505903"]}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2019M653904XB"],"award-info":[{"award-number":["2019M653904XB"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Guangzhou Science and Technology Planning Project","award":["202102010310"],"award-info":[{"award-number":["202102010310"]}]},{"name":"Guangzhou Science and Technology Planning Project","award":["2024A03J0273"],"award-info":[{"award-number":["2024A03J0273"]}]},{"name":"Guangzhou Science and Technology Planning Project","award":["2025A03J3207"],"award-info":[{"award-number":["2025A03J3207"]}]},{"name":"Key R&D Program of Xinjiang Uygur Autonomous Region - Department-Region Linkage Project","award":["2024B04014"],"award-info":[{"award-number":["2024B04014"]}]},{"name":"Key R&D Program of Xinjiang Uygur Autonomous Region - Department-Region Linkage Project","award":["2024B04014-3"],"award-info":[{"award-number":["2024B04014-3"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Recurrent hepatocellular carcinoma (HCC) after liver transplantation remains a formidable challenge. This Phase 1, dose-escalation trial had the \u200bprimary objectives\u200b of evaluating the safety and tolerability of various natural killer (NK) cell infusion regimens in patients with recurrent HCC. \u200bAs exploratory endpoints, the study also assessed preliminary antitumor activity, with progression-free survival (PFS) and overall survival (OS) being key measures of interest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Between December 31, 2014, and March 29, 2017, 18 patients with recurrent HCC after liver transplantation were enrolled in this single-center, Phase I dose-exploration study. Patients were allocated to four treatment groups to receive different frequencies and doses of NK cell infusions alongside conventional treatment. Group A (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20093) received four low-dose infusions, Group B (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) received four normal-dose infusions, Group C (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096) received eight normal-dose infusions, and Group D (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20094) followed an incremental dosing schedule. Treatment-related adverse events (AEs) and survival outcomes were systematically evaluated, with a maximum follow-up period of 9 years.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The most common AE was Grade 1 pyrexia, which typically resolved within a day. The median PFS across the cohort was 4.8 months, with significant differences observed among the groups (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0008). Specifically, the PFS was 1.6 months for Group A, 2.5 months for Group B, 5.5 months for Group C, and 7.5 months for Group D. The median OS was 17.7 months, with notable differences among the groups (log-rank\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.0403). The OS durations were 12.6 months for Group A, 16.1 months for Group B, 18.4 months for Group C, and 31.3 months for Group D.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NK cell infusions were well tolerated and associated with differences in both PFS and OS in patients with recurrent HCC after liver transplantation. Both the frequency and dosage of NK cell infusions are crucial factors influencing survival outcomes, suggesting a potential dose-frequency response relationship.These findings preliminarily underscore the potential of optimizing NK cell-based immunotherapies to enhance clinical outcomes in this challenging patient population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      Trial registration NCT, NCT02399735, Registered 23 March 2015 - Retrospectively registered,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT02399735\" ext-link-type=\"uri\">https:\/\/clinicaltrials.gov\/study\/NCT02399735<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-07725-x","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T16:03:39Z","timestamp":1769270619000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["NK cell infusion is well-tolerated and shows preliminary efficacy in patients with recurrent hepatocellular carcinoma post-liver transplantation : a phase I trial"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-9803","authenticated-orcid":false,"given":"Fan","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihang","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofang","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxi","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jintao","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panlong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunhao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhong","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0635-7746","authenticated-orcid":false,"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"issue":"1","key":"7725_CR1","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Reviews Disease Primers. 2021;7(1):6.","journal-title":"Nat Reviews Disease Primers"},{"issue":"8","key":"7725_CR2","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/S2468-1253(22)00050-4","volume":"7","author":"CJ Alberts","year":"2022","unstructured":"Alberts CJ, Clifford GM, Georges D, Negro F, Lesi OA, Hutin YJ, et al. Worldwide prevalence of hepatitis B virus and hepatitis C virus among patients with cirrhosis at country, region, and global levels: a systematic review. Lancet Gastroenterol Hepatol. 2022;7(8):724\u201335.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"7725_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.livres.2024.05.004","volume":"8","author":"W Abdelhamed","year":"2024","unstructured":"Abdelhamed W, El-Kassas M. Hepatitis B virus as a risk factor for hepatocellular carcinoma: there is still much work to do. Liver Res. 2024;8(2):83\u201390.","journal-title":"Liver Res"},{"issue":"3","key":"7725_CR4","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"7725_CR5","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1038\/s41575-019-0186-y","volume":"16","author":"JD Yang","year":"2019","unstructured":"Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019;16(10):589\u2013604.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"7725_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/17474124.2021.1823213","volume":"15","author":"D Hoffman","year":"2021","unstructured":"Hoffman D, Mehta N. Recurrence of hepatocellular carcinoma following liver transplantation. Expert Rev Gastroenterol Hepatol. 2021;15(1):91\u2013102.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"4","key":"7725_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrgastro.2016.193","volume":"14","author":"G Sapisochin","year":"2017","unstructured":"Sapisochin G, Bruix J. Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches. Nat Rev Gastroenterol Hepatol. 2017;14(4):203\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"4","key":"7725_CR8","first-page":"2379","volume":"13","author":"A Facciorusso","year":"2021","unstructured":"Facciorusso A, Tartaglia N, Villani R, Serviddio G, Ramai D, Mohan BP, et al. Lenvatinib versus Sorafenib as first-line therapy of advanced hepatocellular carcinoma: a systematic review and meta-analysis. Am J Transl Res. 2021;13(4):2379\u201387.","journal-title":"Am J Transl Res"},{"issue":"1","key":"7725_CR9","doi-asserted-by":"publisher","first-page":"100654","DOI":"10.1016\/j.aohep.2021.100654","volume":"27","author":"PD Agarwal","year":"2022","unstructured":"Agarwal PD, Lucey MR. Management of hepatocellular carcinoma recurrence after liver transplantation. Ann Hepatol. 2022;27(1):100654.","journal-title":"Ann Hepatol"},{"issue":"39","key":"7725_CR10","doi-asserted-by":"publisher","first-page":"11185","DOI":"10.3748\/wjg.v21.i39.11185","volume":"21","author":"N de\u2019Angelis","year":"2015","unstructured":"de\u2019Angelis N, Landi F, Carra MC, Azoulay D. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review. World J Gastroenterol. 2015;21(39):11185\u201398.","journal-title":"World J Gastroenterol"},{"issue":"7","key":"7725_CR11","doi-asserted-by":"publisher","first-page":"2286","DOI":"10.1245\/s10434-014-4273-6","volume":"22","author":"G Sapisochin","year":"2015","unstructured":"Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, Rafael E, et al. Benefit of treating hepatocellular carcinoma recurrence after liver transplantation and analysis of prognostic factors for survival in a large Euro-American series. Ann Surg Oncol. 2015;22(7):2286\u201394.","journal-title":"Ann Surg Oncol"},{"issue":"8060","key":"7725_CR12","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1038\/s41586-025-08668-x","volume":"640","author":"G Jia","year":"2025","unstructured":"Jia G, He P, Dai T, Goh D, Wang J, Sun M, et al. Spatial immune scoring system predicts hepatocellular carcinoma recurrence. Nature. 2025;640(8060):1031\u201341.","journal-title":"Nature"},{"issue":"7","key":"7725_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1038\/ni.3482","volume":"17","author":"H Spits","year":"2016","unstructured":"Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat Immunol. 2016;17(7):758\u201364.","journal-title":"Nat Immunol"},{"issue":"2","key":"7725_CR14","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.4110\/in.2020.20.e14","volume":"20","author":"MH Shin","year":"2020","unstructured":"Shin MH, Kim J, Lim SA, Kim J, Kim SJ, Lee KM. NK Cell-Based immunotherapies in cancer. Immune Netw. 2020;20(2):e14.","journal-title":"Immune Netw"},{"issue":"2","key":"7725_CR15","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41577-022-00732-1","volume":"23","author":"NK Wolf","year":"2023","unstructured":"Wolf NK, Kissiov DU, Raulet DH. Roles of natural killer cells in immunity to cancer, and applications to immunotherapy. Nat Rev Immunol. 2023;23(2):90\u2013105.","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"7725_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/cmi.2014.91","volume":"12","author":"C Sun","year":"2015","unstructured":"Sun C, Sun H, Zhang C, Tian Z. NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. Cell Mol Immunol. 2015;12(3):292\u2013302.","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"7725_CR17","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s00262-021-03005-3","volume":"71","author":"M Ohira","year":"2022","unstructured":"Ohira M, Hotta R, Tanaka Y, Matsuura T, Tekin A, Selvaggi G, et al. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma. Cancer Immunol Immunother. 2022;71(3):589\u201399.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"7725_CR18","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41423-024-01145-x","volume":"21","author":"A Page","year":"2024","unstructured":"Page A, Chuvin N, Valladeau-Guilemond J, Depil S. Development of NK cell-based cancer immunotherapies through receptor engineering. Cell Mol Immunol. 2024;21(4):315\u201331.","journal-title":"Cell Mol Immunol"},{"issue":"11","key":"7725_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1182\/blood.2021013972","volume":"139","author":"JJ Bednarski","year":"2022","unstructured":"Bednarski JJ, Zimmerman C, Berrien-Elliott MM, Foltz JA, Becker-Hapak M, Neal CC, et al. Donor memory-like NK cells persist and induce remissions in pediatric patients with relapsed AML after transplant. Blood. 2022;139(11):1670\u201383.","journal-title":"Blood"},{"key":"7725_CR20","doi-asserted-by":"publisher","first-page":"101073","DOI":"10.1016\/j.blre.2023.101073","volume":"60","author":"A Merino","year":"2023","unstructured":"Merino A, Maakaron J, Bachanova V. Advances in NK cell therapy for hematologic malignancies: NK source, persistence and tumor targeting. Blood Rev. 2023;60:101073.","journal-title":"Blood Rev"},{"issue":"6","key":"7725_CR21","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1056\/NEJMoa1910607","volume":"382","author":"E Liu","year":"2020","unstructured":"Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced natural killer cells in CD19-Positive lymphoid tumors. N Engl J Med. 2020;382(6):545\u201353.","journal-title":"N Engl J Med"},{"issue":"8","key":"7725_CR22","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1093\/neuonc\/noaa047","volume":"22","author":"S Khatua","year":"2020","unstructured":"Khatua S, Cooper LJN, Sandberg DI, Ketonen L, Johnson JM, Rytting ME, et al. Phase I study of intraventricular infusions of autologous ex vivo expanded NK cells in children with recurrent Medulloblastoma and ependymoma. Neuro Oncol. 2020;22(8):1214\u201325.","journal-title":"Neuro Oncol"},{"key":"7725_CR23","doi-asserted-by":"crossref","unstructured":"Nguyen R, Sahr N, Sykes A, McCarville MB, Federico SM, Sooter A et al. Longitudinal NK cell kinetics and cytotoxicity in children with neuroblastoma enrolled in a clinical phase II trial. J Immunother Cancer 2020, 8(1).","DOI":"10.1136\/jitc-2019-000176"},{"issue":"17","key":"7725_CR24","doi-asserted-by":"publisher","first-page":"4494","DOI":"10.1158\/1078-0432.CCR-20-0768","volume":"26","author":"SC Lee","year":"2020","unstructured":"Lee SC, Shimasaki N, Lim JSJ, Wong A, Yadav K, Yong WP, et al. Phase I trial of Expanded, activated autologous NK-cell infusions with trastuzumab in patients with HER2-positive cancers. Clin Cancer Res. 2020;26(17):4494\u2013502.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"7725_CR25","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.4143\/crt.2021.986","volume":"54","author":"EJ Kim","year":"2022","unstructured":"Kim EJ, Cho YH, Kim DH, Ko DH, Do EJ, Kim SY, et al. A phase I\/IIa randomized trial evaluating the safety and efficacy of SNK01 plus pembrolizumab in patients with stage IV Non-Small cell lung cancer. Cancer Res Treat. 2022;54(4):1005\u201316.","journal-title":"Cancer Res Treat"},{"issue":"5","key":"7725_CR26","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1172\/JCI132712","volume":"130","author":"M Lin","year":"2020","unstructured":"Lin M, Luo H, Liang S, Chen J, Liu A, Niu L, et al. Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. J Clin Invest. 2020;130(5):2560\u20139.","journal-title":"J Clin Invest"},{"issue":"3","key":"7725_CR27","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/154732804323099235","volume":"13","author":"JM Brand","year":"2004","unstructured":"Brand JM, Meller B, Von Hof K, Luhm J, B\u00e4hre M, Kirchner H, et al. Kinetics and organ distribution of allogeneic natural killer lymphocytes transfused into patients suffering from renal cell carcinoma. Stem Cells Dev. 2004;13(3):307\u201314.","journal-title":"Stem Cells Dev"},{"key":"7725_CR28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2147\/JHC.S505979","volume":"12","author":"S Chen","year":"2025","unstructured":"Chen S, Qi H, Tan H, Cao F, Xie L, Huang T, et al. Long-Term analysis of recurrence beyond Milan criteria following ablation of solitary Early-Stage hepatocellular Carcinoma\u2009\u2264\u20093\u00a0cm in potentially transplantable patients: A over 10-Year survival study. J Hepatocell Carcinoma. 2025;12:205\u201318.","journal-title":"J Hepatocell Carcinoma"},{"key":"7725_CR29","doi-asserted-by":"crossref","unstructured":"Shapiro RM, Birch GC, Hu G, Vergara Cadavid J, Nikiforow S, Baginska J et al. Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. J Clin Invest 2022, 132(11).","DOI":"10.1172\/JCI154334"},{"issue":"4","key":"7725_CR30","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1007\/s12072-023-10524-x","volume":"17","author":"F Yang","year":"2023","unstructured":"Yang F, Zheng X, Koh S, Lu J, Cheng J, Li P, et al. Messenger RNA electroporated hepatitis B virus (HBV) antigen-specific T cell receptor (TCR) redirected T cell therapy is well-tolerated in patients with recurrent HBV-related hepatocellular carcinoma post-liver transplantation: results from a phase I trial. Hepatol Int. 2023;17(4):850\u20139.","journal-title":"Hepatol Int"},{"key":"7725_CR31","doi-asserted-by":"crossref","unstructured":"Morton LT, Wachsmann TLA, Meeuwsen MH, Wouters AK, Remst DFG, van Loenen MM et al. T cell receptor engineering of primary NK cells to therapeutically target tumors and tumor immune evasion. J Immunother Cancer 2022, 10(3).","DOI":"10.1136\/jitc-2021-003715"},{"issue":"1","key":"7725_CR32","doi-asserted-by":"publisher","first-page":"100006","DOI":"10.1016\/j.medp.2024.100006","volume":"1","author":"Z-Y Qian","year":"2024","unstructured":"Qian Z-Y, Duan C-Y, Cao P-H, Li X-X, Cai Z-Z, Li J-B, et al. Delayed treatment effect predicting (DTEP) model for guiding immuno-oncology trial designs. Med Plus. 2024;1(1):100006.","journal-title":"Med Plus"},{"issue":"1","key":"7725_CR33","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1186\/s12885-023-11610-x","volume":"23","author":"M Ahmadvand","year":"2023","unstructured":"Ahmadvand M, Barough MS, Barkhordar M, Faridfar A, Ghaderi A, Jalaeikhoo H, et al. Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. BMC Cancer. 2023;23(1):1090.","journal-title":"BMC Cancer"},{"issue":"1","key":"7725_CR34","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s10238-025-01559-5","volume":"25","author":"M Rady","year":"2025","unstructured":"Rady M, Mostafa M, Dida G, Sabet F, Abou-Aisha K, Watzl C. Adoptive NK cell therapy in AML: progress and challenges. Clin Exp Med. 2025;25(1):41.","journal-title":"Clin Exp Med"},{"key":"7725_CR35","doi-asserted-by":"publisher","first-page":"104553","DOI":"10.1016\/j.critrevonc.2024.104553","volume":"205","author":"JH Tao","year":"2025","unstructured":"Tao JH, Zhang J, Li HS, Zhou Y, Guan CX. Nature killer cell for solid tumors: current Obstacles and prospective remedies in NK cell therapy and beyond. Crit Rev Oncol Hematol. 2025;205:104553.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"7725_CR36","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.stem.2025.03.004","volume":"32","author":"T Deuse","year":"2025","unstructured":"Deuse T, Schrepfer S. Progress and challenges in developing allogeneic cell therapies. Cell Stem Cell. 2025;32(4):513\u201328.","journal-title":"Cell Stem Cell"},{"issue":"5562","key":"7725_CR37","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","volume":"295","author":"L Ruggeri","year":"2002","unstructured":"Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295(5562):2097\u2013100.","journal-title":"Science"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07725-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07725-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:06:43Z","timestamp":1781629603000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07725-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7725"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07725-x","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Third Affiliated Hospital of Sun Yat-sen University (Approval No. (2014)2-126). All participants provided signed informed consent forms prior to enrollment, in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"261"}}